Latest news with #TumorTreatingFields
Yahoo
08-07-2025
- Health
- Yahoo
Hope on the Horizon: Cutting-Edge Therapies Redefine Outcomes in Glioblastoma Multiforme Treatment making the global market to nearly double by 2033 and grow with a CAGR of 8.5%
The glioblastoma multiforme treatment market is expected to grow significantly and reach USD 6.1 billion by 2033, driven by a rising prevalence, growing R&D investment in novel therapies and favorable reimbursement support. New vaccine-based approaches are emerging as key areas of focus. Chicago, July 08, 2025 (GLOBE NEWSWIRE) -- The global glioblastoma multiforme treatment market was valeud at US$ 3.0 billion in 2024 and is expected to reach USD 6.1 billion by 2033, growing at a CAGR of 8.5% from 2025-2033. This expansion is fueled by rising disease prevalence, advances in diagnostics, growing R&D investments, and emerging targeted therapies. However, challenges such as the blood-brain barrier, therapeutic resistance, and limited long-term efficacy constrain progress and deter commercial investment. Despite these hurdles, innovation across therapeutic modalities and supportive technologies is gradually reshaping the treatment landscape. Explore Key Data Points and Forecast Tables in the Free Sample Copy: Glioblastoma Multiforme is the most common type of cancerous brain tumor. It poses significant treatment challenges due to its rapid proliferation, invasive growth, and resistance to conventional therapies. It is characterized by necrosis, microvascular proliferation, and marked cellular atypia. As per the American Association of Neurological Surgeons in 2024, glioblastoma multiforme accounted for 47.7% of malignant brain and CNS tumors, with an incidence of 3.2 per 100,000 and a prevalence of 9.2 per 100,000 in the U.S. According to the National Brain Tumor Society, the median survival is 14.6 months, with only 17% of patients alive after two years and a five-year survival rate of just 6.8%. It is more common in males, peaks between ages 75 – 84, and shows racial disparities, with highest incidence among non-Hispanic white populations. Treatment typically involves surgical resection followed by chemoradiation with temozolomide, which remains the standard of care (SoC). However, recurrence occurs in over 90% of patients within two years. For recurrent cases, bevacizumab (Avastin) and combinations like lomustine-bevacizumab offer modest benefits. Device-based therapies, such as Tumor Treating Fields (TTFields), continue gaining traction with FDA-approved systems like Optune Gio. Novel therapies, including selinexor (NCT04216329) and immune checkpoint inhibitors like nivolumab (NCT04606316), are currently in clinical trials, signaling progress towards durable Forecast (2033) USD 6.1 billion CAGR 8.5% Top Driver (s) Growing Prevalence of glioblastoma multiformeFavorable reimbursement policies Demand for effective treatment Top Trend Adoption of TTFields devices Top Restraint Consistently low survival rates in glioblastoma multiforme Opportunity Unlocked: Glioblastoma Vaccines as the Next Frontier in Immunotherapy Glioblastoma multiforme is hard to treat with conventional therapies. However, breakthroughs in vaccine-based immunotherapy are beginning to reshape the therapeutic landscape, offering new hope for the patients. Research efforts are accelerating around multiple vaccine platforms, including peptide-based, dendritic cell (DC), and mRNA vaccines, highlighting a new era of personalized and immune-driven treatment strategies. Peptide vaccines, such as SurVaxM developed by MimiVax and currently in Phase II clinical trials, are designed to target tumor-specific neoantigens, activating the immune system to selectively attack malignant cells. These personalized vaccines have shown potential in extending progression-free survival and enhancing immune engagement. Similarly, DC vaccines are gaining traction, despite logistical challenges in integration with standard therapies. Notable candidates such as DCVax-L, in Phase III trials for newly diagnosed and recurrent glioblastoma multiforme, and DOC1021, currently in Phase II trials by Diakonos, have demonstrated improved two-year survival rates when administered sequentially after temozolomide (TMZ) chemotherapy, rather than concurrently. Meanwhile, mRNA-based vaccines are emerging as a powerful immunotherapeutic modality, leveraging their rapid development cycle and capacity to induce strong, targeted immune responses against glioblastoma multiforme cells. Their adaptability and precision position them as a key component in next-generation oncology protocols. While the momentum is promising, ongoing research aims to refine delivery systems, address tumor-induced immunosuppression, and explore synergistic combinations with checkpoint inhibitors and standard-of-care therapies. Collectively, the expanding pipeline of glioblastoma vaccines signifies a paradigm shift toward more personalized, immune-based interventions, marking a transformative step forward in the quest for more durable and effective glioblastoma multiforme treatment. Regional Dynamics Shaping the Glioblastoma Multiforme Treatment Landscape The global glioblastoma multiforme treatment market is evolving rapidly, with regional dynamics playing a pivotal role in shaping its growth. North America leads the market, driven by advanced healthcare infrastructure, streamlined regulatory frameworks, and strong R&D investment. The U.S. Consolidated Appropriations Act of 2024 allocated $10 million to establish the Glioblastoma Research Program (GBMRP) under CDMRP, while Canada's Lundin Cancer Fund committed $4 million in 2025 to launch a national glioblastoma multiforme initiative, reinforcing the region's leadership in clinical innovation. Europe follows closely, propelled by coordinated national research strategies and strong public funding. Germany's UNITE Glioblastoma project, supported by the German Research Foundation's Collaborative Research Centers, exemplifies the region's growing commitment to tackling glioblastoma multiforme through advanced research and cross-border collaboration. The Asia-Pacific region is witnessing rapid progress, with governments, academia, and private stakeholders stepping up investment. Japan's conditional approval of DELYTACT (G47∆) the world's first oncolytic virus therapy for malignant gliomas, highlights the region's increasing role in therapeutic innovation. Meanwhile, the Middle East and Africa are in the early stages of glioblastoma multiforme research development. Though challenged by limited infrastructure and funding, emerging efforts from academic centers and private healthcare providers are laying the groundwork for future growth and capacity-building. As glioblastoma multiforme remains one of the most aggressive brain cancers, regional efforts will continue to shape the global response, advancing innovation, access, and treatment outcomes. Recent Advancements and Key Players in the Glioblastoma Therapeutics Market Several prominent players, including Novocure, Roche, Merck & Co., Novartis, Daiichi Sankyo, Allergan, Laminar Pharmaceuticals, Vigeo Therapeutics, Eli Lilly, Incyte Corporation, Kazia Therapeutics, and TVAX Biomedical, are advancing innovation in the glioblastoma treatment landscape. These companies are focused on developing novel therapeutics, targeted drug delivery systems, and strategic collaborations to tackle one of the most aggressive forms of brain cancer. In March 2025, Laminar Pharmaceuticals announced promising results from its ongoing Phase 2b/3 clinical trial (NCT04250922) of LAM561 in newly diagnosed glioblastoma (ndGBM). The randomized, double-blind, placebo-controlled study evaluates LAM561 in combination with standard chemoradiotherapy (radiotherapy and temozolomide). Early data revealed a positive trend in progression-free survival (PFS), particularly in patients with MGMT-methylated tumors. The trial is partially supported by the EU H2020 ClinGlio initiative, reinforcing the importance of public-private partnerships in advancing brain cancer research. Similarly, on June 2, 2025, Sapience Therapeutics presented updated clinical and biomarker data from its ongoing Phase 2 trial of Lucicebtide (formerly ST101) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Lucicebtide, a first-in-class C/EBPβ antagonist, demonstrated encouraging results in glioblastoma patients, further validating its mechanism of action and potential as a novel targeted therapy. Further driving progress, on April 1, 2025, Spanios and GlioGuard announced a strategic partnership to accelerate glioblastoma drug discovery and development. This collaboration aims to deliver more effective and personalized treatment options for glioblastoma multiforme, addressing the urgent need for breakthroughs in one of the most treatment-resistant forms of cancer. These advancements highlight the growing momentum in glioblastoma therapeutics. With continued innovation, clinical progress, and collaborative efforts, the industry is poised to improve patient outcomes and reshape the future of brain cancer treatment. Book a 1:1 Presentation to Discuss Key Trends and Strategic Takeaways: Future Outlook: Evolving the Glioblastoma Multiforme Treatment Landscape The glioblastoma multiforme treatment market is under transformation. By 2030, a combination of drug innovation, device advancement, and integrated care models is expected to redefine survival outcomes for this aggressive brain cancer. Oral therapies currently lead the market, driven by ease of use and improved patient adherence. Injectables follow, offering systemic options like chemotherapies and targeted biologics. Implants, such as localized wafers, remain a niche but vital component post-surgery. Therapies, especially multi-modal regimens, dominate the market and are expanding rapidly, as combination approaches become the clinical standard. The next wave will be led by immunotherapies and immune checkpoint inhibitors, poised to break the disease immune resistance. These emerging treatments will increasingly complement traditional modalities, aiming for longer progression-free and overall survival. Wearable devices, particularly Novocure's Optune Gio, represent a paradigm shift. Future versions will be lighter, more personalized, and AI-integrated, enabling real-time therapy adjustments and remote monitoring, bringing glioblastoma multiforme care closer to the patient. Key Competitors Novocure Roche Merck & Co. Novartis Daiichi Sankyo Allegran Laminar pharmaceuticals Vigeo therapeutics Eli lily Incyte corporation Kazia Therapuetics TVAX Biomedicals Segmentation: Glioblastoma Multiforme Treatment Market By Treatment Type Surgery (Gliadel wafer) Therapies Chemotherapy Temzolomide Lomustine Radiation Therapy Targeted Therapy (Bevacizumab) Others (Delytact) Tumor Treating Fields (TTF) (Optune Gio) By Dosage Form Oral Injectables Implant and TFF Field Device By End Users Hospitals & Clinics (specialty clinics) Cancer Treatment Centers Academic and Research Organizations By Region North America South America Europe Asia Pacific Middle East and Africa Still Have Questions? Contact Us for Clarification or a Custom Data Request: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
01-07-2025
- Business
- Business Wire
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer. These data from PANOVA-3 were accepted as a late-breaking abstract for oral presentation at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025, taking place July 2 to July 5 in Barcelona, Spain. 'In the PANOVA-3 trial, there was a significant improvement in overall survival and a significant delay in the progression of pain as well as delayed opioid medication use in patients treated with Tumor Treating Fields and chemotherapy compared to chemotherapy alone. Pancreatic cancer is associated with debilitating pain. Delaying these symptoms can preserve a patient's overall quality of life, a promising outcome we observed in this trial,' said Teresa Macarulla, MD, PhD, Medical Oncologist at Hospital Universitari Vall d'Hebron and Head of the Gastrointestinal and Endocrine Tumors Group at the Vall d'Hebron Institute of Oncology (VHIO). 'The overall survival and quality of life results in PANOVA-3 support Tumor Treating Fields therapy with gemcitabine and nab-paclitaxel as a potential standard of care for unresectable, locally advanced pancreatic cancer.' The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma, compared to GnP alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival for patients treated with TTFields. 'The PANOVA-3 results illustrate that Tumor Treating Fields therapy can significantly improve clinical outcomes for patients, including overall survival, in unresectable, locally advanced pancreatic cancer,' said Nicolas Leupin, MD, PhD, Chief Medical Officer, Novocure. 'These new data show that Tumor Treating Fields therapy can also have a meaningful impact preserving patients' quality of life by delaying worsening symptoms of pancreatic cancer. We look forward to submitting a premarket application for Tumor Treating Fields therapy to the FDA in the second half of 2025.' Results from PANOVA-3 The primary endpoint of overall survival and several secondary endpoints, including pain-free survival, from PANOVA-3 were previously reported at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The additional secondary endpoint data to be presented at the ESMO Gastrointestinal Cancers Congress 2025 are the full quality of life outcomes as well as a post-hoc analysis of the time to first opioid use. The quality of life outcomes were measured using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with the pancreatic cancer specific PAN26 addendum scales. The EORTC QLQ-C30 and the PAN26 measure global health status and function as well as symptoms including pain (irrespective of cause), pancreatic pain, and gastrointestinal symptoms. There was a statistically significant delay in the time to deterioration in global health status for patients treated with TTFields concomitant with GnP compared to patients treated with GnP alone, with a median of 7.1 months compared to 5.7 months, respectively, p=0.023. The delay in time to deterioration due to pain (irrespective of cause) was statistically significant in patients treated with TTFields concomitant with GnP compared to patients treated with GnP alone, with a median 10.1 months compared to 7.4 months, respectively, p=0.003. Similarly, the delay in time to deterioration due to pancreatic pain was statistically significant in patients treated with TTFields concomitant with GnP compared to patients treated with GnP alone, with a median of 14.7 months compared to 10.2 months, respectively, p=0.006. These results complement the statistically significant extension in pain-free survival reported at the 2025 ASCO Annual Meeting, which was defined as the time between randomization until a ≥20-point increase of pain using a visual analog scale (VAS) from baseline or death. Patients treated with TTFields concomitant with GnP had a median pain-free survival of 15.2 months compared to a median 9.1 months in the group treated with GnP alone; HR 0.74 (95% CI: 0.56–0.97) p=0.027. All gastrointestinal symptom scales included in the EORTC QLQ-C30 and PAN26, except for indigestion and altered bowel habit, significantly favored patients treated with TTFields concomitant with GnP. In a post-hoc analysis, time to first opioid use was significantly longer with TTFields and GnP compared to patients treated with GnP alone, with a median of 7.1 months compared to 5.4 months, respectively, p=0.046. TTFields therapy was well-tolerated, no new safety signals were observed, and device related safety outcomes were consistent with prior clinical studies using TTFields. Mild to moderate skin adverse events (AEs) were the most common device-related AEs. The company will also present two posters of preclinical data from its pancreatic cancer development program. Data Presentation Details Oral Presentation: Late Breaking Abstract #LBA3: PANOVA-3: Pain and quality of life (QoL) outcomes with Tumor Treating Fields (TTFields) therapy in patients with locally advanced pancreatic adenocarcinoma (LAPC) Presenting Author: Teresa Macarulla, MD, PhD, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Spain Time and Location: July 3, 2:10 PM CEST / 8:10 AM EDT, Barcelona Room Poster #311P: Effectiveness of tumor treating fields (TTFields) together with gemcitabine and nab-paclitaxel in pancreatic ductal adenocarcinoma (PDAC) preclinical models Time and Location: July 3, 3:30 – 4:30 PM CEST / 9:30 – 10:30 AM EDT, Exhibition Area Poster #316P: Pancreatic cancer cells are sensitized to FOLFIRINOX treatment by co-application with tumor treating fields (TTFields) Time and Location: July 3, 3:30 – 4:30 PM CEST / 9:30 – 10:30 AM EDT, Exhibition Area About PANOVA-3 PANOVA-3 is an international, prospective, randomized, open-label, controlled Phase 3 clinical trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields) therapy used concomitantly with gemcitabine and nab-paclitaxel, as a first-line treatment for locally advanced pancreatic adenocarcinoma. Patients were randomized to receive either TTFields therapy concomitant with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity. The PANOVA-3 trial enrolled 571 patients who were randomized 1:1 and followed for a minimum of 18 months. About Pancreatic Cancer Pancreatic cancer is one of the most lethal cancers and is the third most frequent cause of death from cancer in the U.S. i and the fifth most frequent cause in Europe. ii While overall cancer incidence and death rates are remaining stable or declining, the incidence and death rates for pancreatic cancer are increasing. iii It is estimated that approximately 67,000 patients are diagnosed with pancreatic cancer each year in the U.S. iv and the global incidence is more than 500,000. v Pancreatic cancer has a five-year relative survival rate of just 13%. vi Physicians use different combinations of surgery, radiation and pharmacological therapies to treat pancreatic cancer, depending on the stage of the disease. For patients with locally advanced pancreatic cancer involving encasement of arteries but no extra-pancreatic disease, the standard of care is surgery followed by chemotherapy with or without radiation. Unfortunately, most locally advanced cases are diagnosed when the cancer is no longer operable, generally leaving chemotherapy with or without radiation as the only treatment option. About Tumor Treating Fields Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit and follow @Novocure on LinkedIn and Twitter. Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as 'anticipate,' 'estimate,' 'expect,' 'project,' 'intend,' 'plan,' 'believe' or other words and terms of similar meaning. Novocure's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion. ii International Agency for Research on Cancer. Cancer TODAY 2024. Data version: Globocan 2022. Accessed June 24, 2025. v International Agency for Research on Cancer. Cancer TODAY 2024. Data version: Globocan 2022. Accessed June 24, 2025. vi American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025
Business Wire
30-06-2025
- Business
- Business Wire
Novocure to Report Second Quarter 2025 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company's financial results for the three- and six-month periods that ended June 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit and follow @Novocure on LinkedIn and Twitter. Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as 'could' 'anticipate,' 'estimate,' 'expect,' 'project,' 'intend,' 'plan,' 'believe' or other words and terms of similar meaning. Novocure's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Yahoo
02-06-2025
- Business
- Yahoo
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The data were presented at the 2025 American Society of Clinical Oncology Annual Meeting. The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) for patients treated with TTFields. In the intent-to-treat population, patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel had an mOS of 16.2 months compared to 14.2 months for patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement. TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints, including one-year and pain-free survival rates. The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group, 68.1%, compared to 60.2% for those who received gemcitabine and nab-paclitaxel alone. Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months compared to a median of 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone. This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until patients reported an increase of 20 or more points on a visual scale for pain or until death. There was no statistically significant difference in additional secondary outcome measures of progression-free survival, local progression-free survival, objective response rate, puncture-free survival, or tumor resectability rate between the TTFields with gemcitabine and nab-paclitaxel and the gemcitabine and nab-paclitaxel arms. TTFields therapy was well-tolerated, no new safety signals were observed, and safety was consistent with prior clinical studies. Mild to moderate skin adverse events (AEs) were the most common device-related AEs. Price Action: NVCR stock is trading lower by 8.63% to $17.46 at last check Monday. Read Next:Photo by Aunt Spray via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
02-06-2025
- Health
- Business Insider
Novocure announces results from Phase 3 PANOVA-3 trial
Novocure (NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields therapy for pancreatic cancer will be presented at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival for patients treated with TTFields. TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints including the one-year survival rate and pain-free survival. The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group with compared to those who received gemcitabine and nab-paclitaxel alone. Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months compared to a median 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone. This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until an increase of 20 or more points was reported by patients on a visual scale for pain or until death.
